In November 2012, I announced my intention to create a portfolio of 10 companies that investors had effectively thrown away and given up on, in the hope of showing investors that deep-value investing and contrarian thinking can actually be a very successful investing method. I dubbed this the "One Person's Trash Is Another Person's Treasure" portfolio, and in each of the past 10 weeks I highlighted a company that I felt fit this bill and would expect to drastically outperform the benchmark S&P 500 over the coming 12 months. If you're interested in the reasoning behind why I chose these companies, then I encourage you to review my synopsis on each portfolio selection:
Today, I plan to officially kick off this experiment.
As I mentioned previously, and for complete transparency purposes, unlike my Foolish colleagues Jim Royal and Brian Stoffel, who are pioneering their own market-beating portfolios, and own each and every company listed in those portfolio, I only own four of the following 10 names but reserve the right to purchase or sell these names as the Fool's disclosure policy allows.
Without further ado, here's the portfolio:
S&P 500 Performance
Performance Relative to S&P 500
Source: Yahoo! Finance.
Buy high, sell higher
One thing you'll notice is that many of these companies have come well off their lows from when I originally highlighted them.
Dell, for instance, has jumped nearly 50% off its lows on confirmed talks that a consortium of buyers, including Silver Lake Partners and Microsoft, could be interested in taking the company private. It appears talks have been ongoing for months and even a failure of the deal could allow it to repurchase an enormous number of shares that'd still be beneficial to shareholders as Dell transitions from a PC company to a cloud-based infrastructure provider.
QLogic shares rallied strongly after it reported third-quarter earnings results that were way ahead of its previous guidance. The news of better-than-expected interconnectivity spending shouldn't come as a surprise, as AT&T recently announced a $14 billion wireless and wireline infrastructure upgrade over the next three years, and Sprint Nextel is expected to use its SoftBank capital infusion on a 4G LTE build-out.
But just because these tech names have jumped doesn't mean I'm counting them out from further upside.
In the news...
In more recent news, we received quarterly reports from both Arkansas Best and Xerox, as well as an analyst upgrade for Dendreon.
Before the bell yesterday, Arkansas Best reported a fourth-quarter adjusted loss of $0.22 on revenue of $537 million. The revenue figure sailed past Wall Street's expectations by nearly $25 million, but its loss was $0.18 worse than expected. Arkansas Best's most pressing issue is its ongoing contract negotiations with its union, but a long-tenured and cohesive management team that can keep costs under control puts my mind at ease that a resolution is nearing.
Xerox reported its fourth-quarter results last week, which showed flat year-over-year sales of $5.92 billion and EPS of $0.30, slightly edging out the $5.88 billion and $0.29 Wall Street had expected. Although Xerox's guidance appears conservative, it's worth noting that its restructuring efforts expanded operating margin by 30 basis points to 10.3% and it appears poised for a big boost in its Medicaid payment processing business next year when the Affordable Care Act goes into full effect.
Finally, Dendreon received a nice boost from Cantor Fitzgerald, which nudged its price target on the biotech company up to $7. Dendreon is facing a pivotal year with Provenge, its late-stage prostate cancer treatment. The European Union is expected to approve or deny the pricey treatment sometime in 2013, but, more important, Dendreon will be looking for ways to partner Provenge with existing and experimental prostate cancer treatments. Combine this with the big cost savings expected to really reflect in Dendreon's bottom line by mid-year, and I think it'll head much higher.
With this being the kickoff, I have little to report on performance other than that commission costs have put me in a 1% hole to the S&P 500. I strongly believe, however, that through share appreciation and dividends, this portfolio can outperform the S&P 500 by double digits over the coming year. It looks to be an exciting year!
Is this the year Dendreon turns its fortunes around?
Dendreon's run over the past four years witnessed sub-$5 share prices skyrocket to 10-bagger status before tumbling all the way back down below $5, as its revolutionary prostate cancer vaccine Provenge became a lightning rod of debate. But where does that leave investors -- other than a bit nauseous from the roller-coaster ride? Our own David Williamson answers this question, and many more, inside our brand new premium research report on Dendreon. Inside, he details every key issue facing the company and outlines just how Dendreon intends to regain its former glory. The report also comes with a full year of analyst updates, so claim your copy of this exclusive report today by clicking here now.
The article One Person's Trash Is Another Person's Treasure Portfolio originally appeared on Fool.com.
Fool contributor Sean Williams owns shares of QLogic, Dell, Skullcandy, and France Telecom, but has no material interest in any other companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.The Motley Fool owns shares of Dendreon, Staples, and France Telecom. Motley Fool newsletter services have recommended buying shares of Exelon and France Telecom, as well as writing puts on Exelon and creating a synthetic covered call position in Microsoft. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.